Recon Strategy
Contact

Insights

Fifteen+ years of
healthcare thinking

Several hundred perspectives on the questions facing payers, providers, biopharma, medtech, and digital health — plus our running read on the clinical literature. Start with our sharpest work, or filter to your world.

Emerging blood-brain barrier drugs in development

  • Biopharma
Despite the historical difficulty in designing therapeutics that cross the BBB, Denali’s landmark approval could signal an inflection point for the BBB-crossing therapeutic pipeline.

Read more